Guardant Health (GH) said Tuesday that Palmetto GBA has granted coverage for the Guardant Reveal test to monitor for disease recurrence in colorectal cancer patients after curative intent therapy, expanding from the prior coverage in the early post-surgical setting only.
Palmetto is a Medicare administrative contractor that administers the Molecular Diagnostics Services program, the firm said.
Shares of Guardant Health were up more than 14% in recent trading.
Price: 42.10, Change: +5.44, Percent Change: +14.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments